Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti–factor XIII autoantibodies.

Introduction: Autoimmune factor XIII (FXIII) deficiency (AiF13D) due to anti‐FXIII autoantibodies is an extremely rare, life‐threatening bleeding disorder that mostly occurs in the elderly. The number of patients diagnosed with AiF13D has been increasing in Japan, probably because of the nationwide survey on AiF13D supported by the Japanese Ministry of Health, Labour and Welfare. Aim: To explore the pathologic characteristics of coagulation parameters in AiF13D. Methods: AiF13D‐suspected cases were consulted, and underwent unified/integrated coagulation screening and were definitively diagnosed as AiF13D separately. Results: AiF13D patients had lower FXIII antigen levels than non‐AiF13D patients, but their values overlapped. Among a series of 22‐item screening tests and their resulting parameters, the 'FXIII inhibitory potential' yielded by a 1:1 mixing test of the patient's and healthy control's plasma and its 'residual FXIII activity' in 54 AiF13D cases were most distinguishable from 139 non‐AiF13D cases, followed by FXIII activity per se and FXIII‐specific activity. While the cross‐linked α2‐plasmin inhibitor level reduced, the levels of D‐dimer, fibrin/fibrinogen degradation products and plasmin‐plasmin inhibitor complex increased, probably because the patients' haematoma nonspecifically induced secondary fibrinolysis in both AiF13D and non‐AiF13D patients. Conclusion: AiF13D appears to induce a hypocoagulopathy combined with a hyper‐fibrinolytic state secondary to severe FXIII deficiency caused by anti‐FXIII autoantibodies, and the consequent bleeding further modifies its pathological conditions. In addition, the 1:1 mixing test of FXIII activity was confirmed to be a reliable screening method for AiF13D, especially when its derivative parameter, such as the 'FXIII inhibitory potential' or 'FXIII inhibitory potential ratio', is employed. [ABSTRACT FROM AUTHOR]